Related Experiment Video

Updated: Jun 18, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Postablation Atrial Fibrillation Recurrence: A Systematic

Yasir Adnan1, Umabalan Thirupathy2, Aya Abouayana3

  • 1From the Department of Cardiology, Sheikh Shakhbout Medical City, Abu Dhabi, UAE.

Cardiology in Review
|June 16, 2026
PubMed

Insights

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) significantly reduce atrial fibrillation (AF) recurrence after catheter ablation. This therapy also lowers mortality and rehospitalization rates, suggesting improved cardiovascular outcomes in AF patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) recurrence post-ablation is a significant clinical issue.
  • Emerging evidence suggests sodium-glucose cotransporter 2 inhibitors (SGLT2i) may mitigate AF recurrence, but data are limited.

Purpose of the Study:

  • To systematically evaluate the efficacy of SGLT2i in reducing post-ablation AF recurrence.
  • To assess the impact of SGLT2i on all-cause mortality and rehospitalization in AF patients undergoing ablation.

Main Methods:

  • A meta-analysis of 14 electronic database studies involving 20,996 patients.
  • Compared outcomes of AF patients receiving SGLT2i versus those not receiving SGLT2i post-catheter ablation.
  • Utilized random-effects models to calculate pooled effect estimates for AF recurrence, mortality, and rehospitalization.

Main Results:

  • SGLT2i therapy significantly reduced AF recurrence (RR: 0.65, P < 0.0001).
  • Associated with decreased all-cause mortality (RR: 0.67, P = 0.01) and rehospitalizations (RR: 0.80, P < 0.0001).
  • Moderate heterogeneity observed; subgroup analyses showed no significant interaction by study design.

Conclusions:

  • SGLT2i therapy demonstrates a substantial reduction in post-ablation AF recurrence and improved cardiovascular outcomes.
  • Current evidence is primarily observational; large-scale randomized controlled trials are necessary for confirmation.
  • Findings may inform future clinical guidelines for AF management.
Keywords:
atrial fibrillationcatheter ablationmeta-analysissodium-glucose cotransporter 2 inhibitors

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter08:00

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter

Published on: June 15, 2015

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...